In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity

Executive Summary

Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.

Advertisement

Related Content

Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
AMAG Pharmaceuticals: Enough Irons In The Fire?
Patent Power: Roche Concedes Case Over Amgen's EPO

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel